[The blocking effects of small interfering RNAs on RS-1 gene functions of herpes simplex virus type 2: new perspectives for targeted antiviral exposure].
A new target has been revealed for therapy for herpes simplex type 2. The target is RS1 mRNA whose activation is a key stage in regulating the expression of the early genes of herpes simplex virus type 2 (HSV-2). The targeted knockdown of the function of this gene by small interfering RNAs (siRNAs) has been found to result in the complete suppression of HSV-2 infection. The designed interfering RNAs are able to interact with both HSV-1 and HSV-2. The findings suggest that siRNAs have protective properties against the cytopathic effect of HSV-2 and cause no toxicity to infected Vero cells.
N D
ND
L'vov
A S
AS
Bavykin
A V
AV
Mel'nichenko
A V
AV
Karpukhin
D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage; D002522:Chlorocebus aethiops; D015967:Gene Expression Regulation, Viral; D055785:Gene Knockdown Techniques; D018259:Herpesvirus 1, Human / Q000187:drug effects*; D018258:Herpesvirus 2, Human / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D017874:Immediate-Early Proteins / Q000235:genetics*; D012333:RNA, Messenger / Q000037:antagonists & inhibitors / Q000235:genetics; D034741:RNA, Small Interfering / Q000008:administration & dosage / Q000235:genetics*; D014709:Vero Cells; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D017874:Immediate-Early Proteins; D012333:RNA, Messenger; D034741:RNA, Small Interfering; C048925:herpes simplex virus, type 1 protein ICP4